UK Plans for Robust Life Sciences Regulation Post-Brexit

As Brexit is finally completed in the UK, from 1 January 2021, the Medicines and Healthcare products Regulatory Agency (“MHRA”) will be the UK’s standalone medicines and medical devices regulator. Transition from the EU allows the UK to offer fully independent regulatory decisions for both devices and pharmaceuticals, both nationally and in joint work with other international regulators. The frequent changes to legislation on these issues will no longer flow through from updates at the EU level. The Medicines and Medical Devices Bill, which has almost completed its passage through Parliament, creates the structure for the UK Government to legislate for updates or changes to our existing laws on human and veterinary medicines, clinical trials, and medical devices at the end of the Brexit Transition Period in January 2021.

Read our client alert.